Given the frequent combination of RET inhibitors with immunotherapeutic agents in the management of other tumor types (Additional file 1: Table S1), these findings may have critical implications for RET as a therapeutic target in ER-negative tumor subtypes (Fig. 3). The gene discussed is RET; the disease is neoplasm.